Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

Lung cancer patients with brain and leptomeningeal metastases usually have poor prognosis. For those patients with EGFR mutations, osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the first choice of treatment. However, drug resistance to osimertinib frequently occurs; and to date...

Full description

Bibliographic Details
Main Authors: Hui Zhang, Yong Wang, Huaguo Wu, Shizhen Zhou, Shuo Li, Xiangji Meng, Rongjie Tao, Jinming Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
olaparib
dacomitinib
osimertinib-resistant
brain and leptomeningeal metastases
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.877279/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.877279/full

Similar Items